Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will announce its Q2 2022 financial results on August 15, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on novel therapies for Alzheimer’s disease and is advancing its investigational drug, ACU193, in a Phase I clinical trial. Acumen has established itself in the biopharmaceutical sector, targeting the toxic Aβ oligomers linked to Alzheimer’s pathology. The audio from the call will be accessible via their website, with an archived version available for 30 days.

Positive

• Upcoming Q2 2022 financial results announcement on August 15, 2022.
• Advancement of investigational immunotherapy drug ACU193 in Phase I clinical trial.

Negative

• None.

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the Company will report its financial results for the second quarter 2022 on Monday, August 15, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The audio will be available via this link.

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AβOs in INTERCEPT-AD, a Phase I clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Contacts:

Media:
AcumenPR@westwicke.com

Investors:
investors@acumenpharm.com

FAQ

When will Acumen Pharmaceuticals report its Q2 2022 financial results?

Acumen Pharmaceuticals will report its Q2 2022 financial results on August 15, 2022.

What time is the conference call for Acumen Pharmaceuticals Q2 results?

The conference call for Acumen Pharmaceuticals' Q2 results is scheduled for 4:30 p.m. ET.

What is ACU193?

ACU193 is an investigational immunotherapy drug targeting toxic Aβ oligomers, currently in Phase I clinical trials.

How can I access the audio from the Acumen Pharmaceuticals conference call?

The audio from the Acumen Pharmaceuticals conference call can be accessed via their website after registration.